Custom In Vivo Tumor Model Services

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

PC-3 Enzalutamide-Resistant CRPC Model Service

Fig 1: PC-3 Enzalutamide-Resistant CRPC Model preclinical research.

The PC-3 Enzalutamide-Resistant CRPC Model Service supplies a rigorously validated in vitro and in vivo platform for studying therapy resistance in castration-resistant prostate cancer (CRPC) under prolonged androgen receptor (AR) pathway blockade. Alfa Cytology brings this model to clients as a complete preclinical package—chronic, stepwise enzalutamide selection in AR-negative PC-3 cells, resistance-index benchmarking against matched parental controls, mechanism-oriented signaling and phenotypic profiling, and optional resistant xenograft cohorts with drug-treatment arms in immunodeficient mice—so that AR-independent resistance programs can advance on a solid, well-documented foundation.

Overview of PC-3 Enzalutamide-Resistant CRPC Model

The PC-3 enzalutamide-resistant CRPC model is developed from PC-3, a classic human prostate adenocarcinoma cell line originally isolated from a bone metastasis of a patient with grade IV prostate cancer. PC-3 is androgen-independent and lacks functional androgen receptor (AR) expression, carrying instead a PTEN-null, p53-mutant genomic background; it has long served as one of the standard backgrounds in which AR-independent, castration-resistant disease is studied. Because enzalutamide is an AR signaling inhibitor, PC-3 cells show only limited direct sensitivity to the drug; nevertheless, chronic enzalutamide exposure selects subclones that grow preferentially in its presence and display a reduced response to subsequent AR-axis–directed therapy. These resistant derivatives—denoted in the literature as PC-3-ENZR or similar—reproduce a clinically important scenario: tumors that progress on enzalutamide despite lacking AR dependency, and whose growth is instead sustained by bypass signaling networks.

Fig 2: Reference figures for PC-3 Enzalutamide-Resistant CRPC Model. Fig 1. SPP1-integrin signaling in the PC-3 enzalutamide-resistant model: SPP1 binds integrin αvβ3/PTGER4/CD44 complex to activate PI3K-AKT-mTOR and ERK1/2, with JAK2-STAT3, GSK-3β-β-catenin, HIF-1α-Twist converging on EMT (Vimentin/N-cadherin↑, E-cadherin↓). (Pang, Xiaocong, et al., 2021)

Mechanistically, resistance acquired by PC-3 under enzalutamide pressure is dominated by AR-independent routes that are now recognized as major drivers of post-enzalutamide progression. Selected populations characteristically show hyperactivation of STAT3 and the interleukin-6 (IL-6)/JAK/STAT3 axis, rewired PI3K/AKT/mTOR and MAPK/ERK signaling, up-regulation of glucocorticoid receptor activity, and elevated drug-efflux transporter expression. Phenotypically, resistant PC-3 cells frequently acquire a mesenchymal, stem-like state—reduced E-cadherin with increased vimentin and N-cadherin, enhanced clonogenic and sphere-forming capacity, and heightened autophagic flux. Because enzalutamide regimens in xenograft studies (commonly 10 mg/kg daily by oral gavage in castrated or intact immunodeficient mice) fail to suppress tumors derived from these resistant cells, the paired parental/resistant PC-3 system enables researchers to dissect AR-independent resistance biology and to screen rational combination strategies, such as STAT3 or AKT pathway blockade, in both cultured cells and whole-tumor settings.

Principles of PC-3 Enzalutamide-Resistant CRPC Model Construction

Construction of the model is based on chronic adaptive selection with a second-generation antiandrogen in an AR-negative background. Because PC-3 does not depend on AR signaling for survival, the selection window must be calibrated against the line’s intrinsic (and relatively high) enzalutamide IC₅₀: exposure begins at a moderate, growth-permissive concentration and is raised stepwise over many months, alternating drug-on selection phases with drug-off recovery phases. Cells that tolerate each increment—typically those with reinforced bypass signaling, enhanced efflux, or a mesenchymal phenotype—expand until they dominate the culture. The resulting phenotype is verified to persist after drug withdrawal before the subline is considered established.

Principle / Parameter	Detailed Description
Cell background	PC-3 human prostate adenocarcinoma cells, androgen-independent and AR-negative, grown adherently in complete medium (e.g., F-12K or RPMI 1640 with 10% FBS) in a 37 °C, 5% CO₂ incubator.
Selection agent	Enzalutamide (MDV3100), a second-generation AR signaling inhibitor, dissolved in DMSO and applied directly to culture medium as chronic or intermittent exposure cycles.
Exposure regimen	Stepwise escalation beginning around 5–10 µM (near or below the parental growth-inhibitory threshold) and increasing incrementally (by roughly 2–5 µM per cycle) over 6–12 months until cells proliferate stably at a high maintenance concentration of 20–40 µM.
Selection cycle design	Drug-on phases of days to weeks are alternated with drug-off recovery phases; medium is refreshed every 2–3 days during exposure, and cultures are closely monitored because AR-negative cells can shed viability quickly above the selection threshold.
Phenotype stabilization	The resistant pool is maintained under selection pressure for extended passages, then rested in enzalutamide-free medium for one to two weeks to confirm heritability and exclude drug carryover effects.
Core resistance mechanisms	AR-independent bypass signaling: IL-6/JAK/STAT3 hyperactivation, PI3K/AKT/mTOR and MAPK/ERK rewiring, glucocorticoid receptor up-regulation, ABC transporter–mediated drug efflux, enhanced autophagic flux, and metabolic adaptation.
Phenotypic drift	Resistant cells commonly acquire EMT-like features (E-cadherin down, vimentin/N-cadherin up), increased clonogenic, sphere-forming, and migratory capacity, and reduced doubling time variability under drug pressure.
Resistance quantification	Enzalutamide dose–response curves of resistant versus parental cells are measured by MTT or CCK-8 assay, and the resistance index (RI) is calculated from IC₅₀ values; clonogenic and sphere assays corroborate long-horizon fitness.
In vivo extension	Resistant PC-3 cells are implanted subcutaneously into immunodeficient mice (typically 5 × 10⁶ cells per site, often with Matrigel), and enzalutamide treatment arms (commonly 10 mg/kg daily by oral gavage) document the growth advantage of resistant tumors over parental xenografts.

Our Services

Guided by calibrated selection windows and paired-control study design, Alfa Cytology delivers the PC-3 enzalutamide-resistant CRPC model as a turnkey preclinical asset: clients receive authenticated resistant cell banks with quantified resistance indices, matched parental controls, signaling and EMT-marker profiling, and—where a whole-tumor readout is required—resistant xenograft cohorts with enzalutamide treatment arms, all captured in traceable study reports ready for downstream combination-screening programs.

Workflow of PC-3 Enzalutamide-Resistant CRPC Model Construction

Model construction is a multi-month, escalation-based program in which each concentration step is gated by demonstrated regrowth, and each milestone is confirmed with quantitative sensitivity testing against parental controls. Baseline characterization of the parental line precedes selection; phenotypic confirmation precedes molecular profiling; and an optional xenograft stage extends validated resistance into immunodeficient mice. The typical sequence is as follows:

Parental line qualification and baseline profiling: PC-3 cells are revived, authenticated, and mycoplasma-tested; baseline enzalutamide IC₅₀, doubling time, AR-negative status, and basal signaling levels (STAT3, AKT, ERK) are documented as reference values.
Initiation of chronic exposure: Early-passage adherent cells are exposed to a moderate enzalutamide concentration (about 5–10 µM) with medium refreshed every 2–3 days, while morphology and viability are recorded daily.
Stepwise dose escalation: Once cultures demonstrate stable regrowth, the concentration is raised incrementally (by roughly 2–5 µM per cycle) over 6–12 months until cells proliferate robustly at a maintenance level of 20–40 µM.
Stabilization and drug-free rest: The resistant pool is passaged continuously under selection pressure, then cultured without enzalutamide for one to two weeks to verify that the reduced response is heritable and not residual-drug carryover.
In vitro resistance confirmation. Enzalutamide dose–response curves are generated by MTT/CCK-8 assay for parental and resistant cells, the resistance index is calculated from IC₅₀ values, and clonogenic and sphere-formation assays confirm long-term fitness under drug pressure.
Molecular and phenotypic profiling: Signaling readouts (p-STAT3, p-AKT, p-ERK, GR expression), EMT markers (E-cadherin, vimentin, N-cadherin), stemness and migration assays, and drug-efflux or autophagy assays map the resistance landscape.
Resistant xenograft establishment (optional: in vivo stage). Validated resistant cells are inoculated subcutaneously into immunodeficient mice (typically 5 × 10⁶ cells per site, often with Matrigel), and enzalutamide treatment arms (commonly 10 mg/kg daily by oral gavage) benchmark resistant tumors against parental xenografts.
Quality control and release: A release package covering authentication, mycoplasma status, passage history, resistance-index reports, molecular profiling, and xenograft characterization is finalized before the model is delivered for study use.

Fig 3: Workflow for the establishment of PC-3 Enzalutamide-Resistant CRPC Models. Fig 2. PC-3 Enzalutamide-Resistant CRPC Model Construction Workflow.

Case Study-PC-3 Enzalutamide-Resistant CRPC Model Development

In a representative preclinical engagement, the Alfa Cytology team developed and characterized an enzalutamide-resistant PC-3 subline for a client investigating rational combination strategies against AR-independent CRPC progression. Sustained stepwise selection produced a stable resistant population with a clearly elevated resistance index relative to parental cells, and profiling highlighted bypass-signaling activation together with an EMT-like phenotypic shift. The validated subline was applied to combination-treatment screening, and complementary xenograft studies with enzalutamide treatment arms contextualized cellular findings at the whole-tumor level. Engagement-specific datasets and study reports from this and similar programs are available upon request under confidentiality.

Fig 4: Case Study-PC-3 Enzalutamide-Resistant CRPC Model Development.

Why Choose Alfa Cytology?

Alfa Cytology combines calibrated antiandrogen-selection expertise with strict paired-control design, ensuring that every PC-3 enzalutamide-resistant model is stable, well-documented, and immediately useful for AR-independent resistance research. Distinct reasons to work with us include:

Calibrated selection windows tailored to the intrinsic enzalutamide threshold of AR-negative PC-3 cells.
Quantitative resistance-index benchmarking against matched parental controls with orthogonal assay confirmation.
Mechanism-focused profiling spanning bypass signaling, EMT markers, stemness, efflux, and autophagy.
Optional in vivo stage featuring resistant xenografts with standard enzalutamide treatment arms.
Full traceability via authentication, mycoplasma screening, passage logs, and milestone-based reporting.
Confidential, adaptive project management shaped around combination-screening timelines.

Contact Us

If your CRPC research requires a validated enzalutamide-resistant model, contact us today to discuss how the PC-3 enzalutamide-resistant CRPC model can strengthen your preclinical program. Reach out to the Alfa Cytology team for a customized study plan, timeline, and quotation aligned with your objectives.

Reference

Pang, Xiaocong, et al. "SPP1 promotes enzalutamide resistance and epithelial‐mesenchymal‐transition activation in castration‐resistant prostate cancer via PI3K/AKT and ERK1/2 pathways." Oxidative medicine and cellular longevity 2021.1 (2021): 5806602.

For research use only. Not intended for any clinical use.